Open Access

Intravesical Therapy of Superficial Urothelial Bladder Cancer with BCG and Epirubicin 50 Mg - Comparative Analysis

, , , ,  and   
Jul 13, 2022

Cite
Download Cover

1. Ganev T, Petkova L, Statelov T, Stamboliyski V, Hinev A, Evtimov N. Clinical experience in the treatment of invasive bladder cancer. Uronet. 2011;3:29-34. Search in Google Scholar

2. Evtimov N, Ganev T, Stamboliyski V. Complications in the choice of laparoscopic surgical technique. Urology. 2015:2;36-41. Search in Google Scholar

3. Arends TJ, Nativ O, Maffezzini M. et al. Results of a Randomised Controlled Trial Comparing Intravesical Chemohyperthermia with Mitomycin C Versus Bacillus Calmette-Guérin for Adjuvant Treatment of Patients with Intermediate- and High-risk Non-Muscle-invasive Bladder Cancer. Eur Urol. 2016 Jun;69(6):1046-52.10.1016/j.eururo.2016.01.00626803476 Search in Google Scholar

4. Chou R, Selph S, Buckley DI. et al. Intravesical Therapy for the Treatment of Nonmuscle Invasive Bladder Cancer: A Systematic Review and Meta-Analysis. J Urol. 2017 May;197(5):1189-99.10.1016/j.juro.2016.12.09028027868 Search in Google Scholar

5. Redelman-Sidi G, Glickman MS, Bochner BH. The mechanism of action of BCG therapy for bladder cancer - a current perspective. Nat Rev Urol. 2014 Mar;11(3):153-62.10.1038/nrurol.2014.1524492433 Search in Google Scholar

6. Porten SP, Leapman MS, Greene KL. Intravesical chemotherapy in non-muscle-invasive bladder cancer. Indian J Urol. 2015 Oct-Dec;31(4): 297-303.10.4103/0970-1591.166446462691326604440 Search in Google Scholar

Language:
English
Publication timeframe:
2 times per year
Journal Subjects:
Medicine, Clinical Medicine, Clinical Medicine, other, Ophthalmology, Public Health, Pharmacy, Clinical Pharmacy